Semaglutide vs Tirzepatide vs Teriparatide vs Abaloparatide vs Glycopyrrolate: Peptide API Comparison — CAS, Synthesis Route, Patent Cliff & Export Volume

One of these five weighs 398 daltons and is finished in two synthetic steps. The other four weigh between 3,960 and 4,814 daltons and are assembled one amino acid at a time. Glycopyrrolate (CAS 596-51-0) is a quaternary ammonium anticholinergic made by classical organic synthesis, shipped at room temperature and free of any compound patent since the 1960s. Teriparatide (CAS 52232-67-4) and abaloparatide (CAS 247062-33-5) are 34-residue bone-anabolic peptides dosed in micrograms. Semaglutide (CAS 910463-68-2) and tirzepatide (CAS 2023788-19-2) are lipidated incretin peptides dosed in milligrams, and their demand is the reason China's peptide reactor capacity moved from hundred-kilogram to tonne scale in three years. The five share a category label — injectable prescription API — and almost nothing else.

1. Five-Way Snapshot: The Core Comparison Table

Five compounds, three receptor families, two manufacturing technologies, and a commercial range that runs from a molecule with no patent protection remaining to a molecule protected in every major market until 2036.

Three groupings matter more than any individual row. The anticholinergic group is glycopyrrolate alone. The PTH1R group is teriparatide and abaloparatide. The incretin group is semaglutide and tirzepatide. Capacity, cold chain, documentation depth and capital intensity all follow the group, not the individual molecule.

2. Two Manufacturing Universes: Flask Synthesis vs Resin Synthesis

The dividing line in this comparison is not therapeutic category. It is whether the molecule is built in solution or on a solid support.

Glycopyrrolate: classical ester synthesis

• Route. Esterification of a cyclopentylmandelic acid derivative with a 3-hydroxy pyrrolidine, followed by quaternisation with methyl bromide to give the permanently charged pyrrolidinium. Two bond-forming operations, both established for decades.
• Purification. Crystallisation. No preparative chromatography at commercial scale, no lyophilisation.
• Physical form and handling. White crystalline powder, melting point 191–195 °C, freely soluble in water, methanol and ethanol, practically insoluble in chloroform and ether, log P −1.18. Ambient storage, no cold chain.
• Scale economics. Gram-per-patient dosing means kilograms to tonnes of API per year globally, produced by a broad multi-source base at generic prices.

The four peptides: stepwise assembly and chromatographic purification

• Route. Fmoc solid-phase peptide synthesis (SPPS), liquid-phase or hybrid fragment condensation, or recombinant expression. Each residue is coupled and deprotected in a cycle; for a 39-residue chain such as tirzepatide, that is 38 couplings before cleavage.
• Yield arithmetic. Coupling yield compounds across the chain. A 99.5% per-step yield over 38 couplings returns roughly 83% before any purification losses, which is why crude purity, and therefore purification load, is the dominant cost driver for the long peptides.
• Post-chain chemistry. Semaglutide and tirzepatide additionally carry a lipidated side chain installed through a linker on a lysine ε-amino group. The lipidation step and the linker chemistry are separate unit operations on top of chain assembly.
• Purification and isolation. Preparative reversed-phase HPLC followed by lyophilisation. Purification, not synthesis, is usually the capacity bottleneck, and it is expressed in reactor volume and column-hours rather than in flask size.

Impurity universes

The two technologies generate structurally different impurity profiles, and an analytical package built for one is not transferable to the other.

• Small molecule. Process-related impurities, residual starting materials and reagents, diastereomeric ratio, residual solvents under ICH Q3C, elemental impurities under ICH Q3D, polymorph and particle-size control.
• Peptide. Deletion and insertion sequences, incompletely deprotected chains, D-isomers from racemisation during coupling, oxidised methionine, aspartate isomerisation and deamidation, truncated and acetylated species, aggregates, plus counter-ion (acetate or trifluoroacetate) and residual water.

3. CAS Numbers, Sequences & Identity Traps

Physicochemical values below are compiled from published regulatory labels, pharmacopoeial and reference sources; they are indicative for comparison and are not specification limits.

Sequences

Identity traps in this group

• Glycopyrrolate exists as two different masses with one CAS number. The bromide salt is C₁₉H₂₈BrNO₃ at 398.33 g/mol; the glycopyrronium cation is 318.43 g/mol. The FDA label states that the active moiety, glycopyrronium, constitutes 80% of the nominal tablet strength — 1 mg of glycopyrronium bromide corresponds to 0.8 mg of glycopyrronium. A specification written against one basis and a lot assayed against the other produces an 20% discrepancy.
• USAN and INN differ for the same substance. Glycopyrrolate is the United States Adopted Name; glycopyrronium is the International Nonproprietary Name. Both refer to CAS 596-51-0 in its bromide form.
• Teriparatide and abaloparatide are both 34 residues and both act at PTH1R, and are not substitutes. Sequence homology between the two is 41%. They favour different receptor conformations and different signalling durations, and they differ in labelled dose, presentation and patent position.
• Abaloparatide is listed with two hydrogen counts in circulation. The FDA label gives C₁₇₄H₃₀₀N₅₆O₄₉ at 3961 daltons; several chemical databases carry C₁₇₄H₂₉₉N₅₆O₄₉ at approximately 3959.6. Both resolve to CAS 247062-33-5, and the difference changes the fourth significant figure of the mass.
• Semaglutide and tirzepatide are both lipidated, and the lipid chains differ. Semaglutide carries a C18 fatty diacid through an AEEAc-AEEAc-γ-Glu linker; tirzepatide carries a C20 fatty diacid directly on a lysine side chain. Neither is a generic version of the other, and neither shares an impurity profile with an unlipidated peptide.
• Semaglutide's molecular weight is published across a narrow range. Values from 4113.58 to 4113.64 g/mol appear across reference sources, depending on whether average or monoisotopic mass is reported. The mass basis belongs in the analytical method description.

4. Glycopyrrolate — The 398-Dalton Quaternary Ammonium

Glycopyrrolate is the control case in this comparison: the only molecule that is made by ordinary synthetic chemistry, stored at room temperature and priced as a mature generic.

Chemistry and pharmacology

• Structure. Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-, bromide. The permanently charged quaternary ammonium is the reason the molecule does not cross the blood–brain barrier to a significant degree, which is the pharmacological basis for its comparatively low central anticholinergic burden relative to atropine or scopolamine.
• Stereochemistry. The substance contains two chiral centres and is supplied as a racemate of a 1:1 mixture of the R,S and S,R (threo) diastereomers. Both diastereomers are pharmacologically active.
• Physicochemical profile. White crystalline powder, melting point 191–195 °C, freely soluble in water, methanol and ethanol, practically insoluble in chloroform and ether, log P −1.18.

Labelled presentations and where the API goes

5. Teriparatide — PTH(1-34), the Bone-Anabolic Reference

Teriparatide is the 34 N-terminal amino acids of human parathyroid hormone. It is the reference compound for the entire bone-anabolic category and the molecule with the longest post-patent history in this comparison.

Post-patent history

• Patents on the originator product expired in both Europe and the United States in August 2019.
• United States. PF708 was approved by the FDA on 4 October 2019 through a 505(b)(2) new drug application referencing Forteo, on the basis of a 24-week study in 181 patients with osteoporosis; it was launched as Bonsity in June 2020. Teriparatide was not on the FDA's transition list to biologic regulation, which is why the follow-on route was 505(b)(2) rather than a biosimilar application, and why a therapeutic-equivalence rating rather than an interchangeability designation was the available outcome.
• Europe. Biosimilar teriparatides from Stada Arzneimittel and Gedeon Richter were authorised in January 2017; Qutavina and Livogiva in August 2020; Sondelbay in March 2022; Kauliv in February 2023.
• Canada. Osnuvo was approved in January 2020.

6. Abaloparatide — PTHrP(1-34) Analog and the RG Conformation

Abaloparatide and teriparatide are the same length, act at the same receptor and are the two molecules most often mistaken for one another in enquiries. The difference is conformational, and it is the reason both exist.

Non-coded residues are a manufacturing note for both bone peptides: abaloparatide contains Aib (2-aminoisobutyric acid), a sterically hindered residue that complicates coupling efficiency at that position, and carries a C-terminal amide rather than a free acid.

7. Semaglutide — The Lipidated GLP-1 That Rescaled Peptide Capacity

Semaglutide is the molecule that moved peptide API from a specialty category into a capacity-planning problem for the entire Chinese API sector.

Capacity consequences

• Purification, not synthesis, sets the ceiling. The lipidation step and the linker add unit operations after chain assembly, and preparative HPLC throughput is the binding constraint for every manufacturer in the category.
• Capacity is being built in reactor litres. Published figures for the Chinese sector show SPPS reactor volume rising from 41,000 L at the end of 2024 toward a stated 100,000 L target at one CDMO, and from roughly 30,000 L toward 44,000 L at another, alongside tonne-scale workshops with single-batch outputs above 10 kg for long-chain modified peptides such as semaglutide and tirzepatide.
• Alternative routes are being industrialised. Fermentation-based peptide production has been reported at pilot scale for semaglutide API, with stated plans well above current output; if the cost basis works at scale, it changes the purification economics rather than the molecule.

8. Tirzepatide — Dual GIP/GLP-1 and the Longest Patent Runway

Tirzepatide is the longest chain in this comparison, the largest molecule by mass, and the one with the longest remaining period of patent protection.

9. Dose Mass: Why One API Needs Tonnes and Another Needs Kilograms ★

Labelled dose multiplied by dosing frequency gives a quantity that no market report states and that every capacity plan depends on: the mass of API consumed by one treated patient in one year. The figures below are arithmetic from published label regimens and are stated before titration waste, overfill, rejection and process yield.

10. Global Export Volume Ranking (China API Supply) ★

The decisive question in this category is which of the five is actually moving cross-border volume. The ranking below is a qualitative index based on relative API trade activity — weighted by transaction value and enquiry density rather than by shipped mass — from Chinese and other Asian supply chains. It is a directional market view, not a published statistical series, and the ordering separates the two incretins from the remaining three by more than an order of magnitude.

1. Semaglutide (CAS 910463-68-2) — the largest peptide API line in the group by a wide margin. Diabetes, weight management, cardiovascular risk reduction and chronic kidney disease indications stack on the same molecule, and the China compound patent expired on 20 March 2026 while protection in the United States, Europe and Japan runs to 2031–2032. More than ten domestic Chinese filers had submitted generic or biosimilar applications, with further filings reported from Qilu, CSPC, Chengdu Beite, Huadong Medicine and United Laboratories, and chemically-modified generics expected from the third quarter of 2026. Demand spans GMP API, clinical-trial material and research-grade channels, and the qualified-supplier field is still narrow relative to the enquiry volume.
2. Tirzepatide (CAS 2023788-19-2) — comparable demand, longer runway, tighter supply. Combined originator revenue exceeded USD 10.1 billion in a single quarter of 2025. Compound protection runs to 2036 in China and the United States with peripheral patents to 2039–2041, so there is no lawful generic channel in any major market, and API movement is concentrated in clinical, contract-manufacturing and research channels. At 39 residues it is also the most synthesis-intensive molecule in the group.
3. Glycopyrrolate (CAS 596-51-0) — the only high-mass, low-unit-value line. No patent, no cold chain, mature multi-source competition and steady hospital, respiratory and dermatology demand. By shipped mass it is plausibly the largest of the five; by value per kilogram it is the smallest by two to three orders of magnitude. Its position in the index reflects transaction value and enquiry density rather than tonnage.
4. Teriparatide (CAS 52232-67-4) — mature, post-patent, kilogram-scale. Originator patents expired in 2019 and follow-on or biosimilar products are authorised in the United States, the European Union and Canada. Volume is constrained by the label rather than by supply: at 20 µg daily, annual API requirement is measured in single-digit kilograms for a patient population in the hundreds of thousands. Competition among API suppliers is on documentation status and on the impurity package rather than on capacity.
5. Abaloparatide (CAS 247062-33-5) — the smallest line in the group. A 2017 approval with a narrower labelled population and a smaller installed base than teriparatide, and the lowest enquiry density of the five. Realistic orders are kilogram-scale or below, and the manufacturing barrier — Aib incorporation, C-terminal amidation, 34-residue purification — is high relative to the volume, which keeps unit cost elevated.

11. Patent Position & the March 2026 Semaglutide Cliff in China ★

Patent status, not chemistry, determines which of these molecules can be lawfully sourced as a generic API and in which market. The spread across the five is the widest single differentiator in the group.

A second, separate regulatory boundary: compounding channels

Shortage-driven compounding was a material demand channel for both incretins in the United States, and that channel has closed. The FDA declared semaglutide injection in shortage in August 2022 and tirzepatide injection in December 2022; both were removed from the shortage list in late 2024 — tirzepatide in October and semaglutide injection in December. Enforcement discretion for compounding then ended on a staggered schedule: 503A pharmacies for tirzepatide in February 2025, 503B outsourcing facilities for tirzepatide in March 2025, 503A pharmacies for semaglutide in April 2025 and 503B facilities for semaglutide in May 2025.

12. Solubility, Delivery & Formulation Reality

Each of the five presents a different delivery problem, and in four of the five the delivery problem is the reason the product exists in its current form.

13. Synthesis Difficulty, Storage & Cold Chain

Degradation pathways worth specifying

• Oxidation. Teriparatide carries two methionine residues, and methionine oxidation reduces activity; methionine-containing peptides are handled under oxygen-limited conditions.
• Freeze–thaw. Repeated freeze–thaw of peptide solutions inactivates a fraction of the material each cycle; aliquoting after first dissolution is the standard laboratory handling response. The approved teriparatide solution must not be frozen and must not be used if it has been frozen.
• Aggregation and precipitation. Reconstituted lyophilised PTH(1-34) has been reported to precipitate within two to four weeks depending on concentration and temperature. Peptide concentration and temperature history belong in the stability protocol.
• Light. Light protection is written into the handling of teriparatide at the finished-product level, and light-protected storage is standard for the lyophilised peptides generally.
• Counter-ion. Acetate and trifluoroacetate are the two counter-ions encountered after preparative HPLC. The identity and quantity of the counter-ion affect peptide content, solubility and the residual-solvent statement.

14. HS Classification & Export Documentation

Classification of the four peptides and the one small molecule follows two different headings, and both have published United States rulings for two of the five.

Documentation expected on a peptide or anticholinergic API shipment

15. API Selection Guide for Formulation Projects

1. Which manufacturing universe does the project sit in? Small-molecule synthesis with crystallisation and ambient storage, or solid-phase assembly with preparative chromatography and lyophilisation. Capital, lead time and analytical depth diverge at this point and everything downstream follows.
2. Is the target a peptide at all? Glycopyrrolate is the only non-peptide in the group, and it is the only one with no cold chain, no compound patent and a broad multi-source base.
3. Is the receptor PTH1R or an incretin receptor? Teriparatide and abaloparatide are bone-anabolic PTH1R agonists with microgram dosing and kilogram-scale annual API requirement. Semaglutide and tirzepatide are incretin-receptor agonists with milligram dosing and tonne-scale requirement.
4. Does the receptor-conformation profile matter to the programme? Teriparatide engages R0 relatively strongly, giving prolonged cAMP signalling; abaloparatide is RG-selective, giving a shorter response. The two are the same length and the same receptor and are not interchangeable.
5. Which market is the finished product destined for? Semaglutide's compound patent lapsed in China in March 2026 and runs to December 2031 in the United States; tirzepatide runs to 2036 in both. The lawful sourcing position is set by the destination, not by the molecule.
6. What is the declared end use? Licensed finished-dose manufacture with an open DMF or CEP, clinical supply, or research use occupy different regulatory positions, and United States compounding enforcement discretion for both incretins ended during 2025.
7. Is the mass basis defined? Glycopyrrolate has a bromide-salt and a cation basis differing by 20%; each peptide carries a counter-ion and a variable water content. Purity, peptide content, water and counter-ion belong in the specification together.

16. Frequently Asked Questions

17. Conclusion

Five molecules, and the most useful thing that can be said about them is that they do not belong to one market. Glycopyrrolate is a 398-dalton quaternary ammonium salt finished in two operations, shipped at room temperature, free of compound patent since the 1960s, and the heaviest API per treated patient-year in the group at roughly 2.19 grams. Teriparatide and abaloparatide are 34-residue PTH1R agonists dosed in micrograms, one post-patent since 2019 and one RG-selective, together requiring single-digit to tens of kilograms of API per year. Semaglutide and tirzepatide are lipidated incretin peptides dosed in milligrams, and their demand is what moved China's peptide sector from hundred-kilogram to tonne-scale manufacturing inside three years.

Three facts decide most sourcing outcomes in this group. Patent position is jurisdictional, not molecular — semaglutide's China compound patent lapsed in March 2026 while the United States compound patent runs to December 2031 and tirzepatide's runs to 2036 in both. Mass basis is explicit or it is ambiguous — glycopyrrolate has a bromide and a cation basis differing by 20%, and every peptide carries a counter-ion and a water content that separate chromatographic purity from actual peptide content. Capacity is a purification constraint, not a synthesis constraint — reactor litres and column-hours, and a 300-fold spread in API mass per treated patient-year between the top and bottom of the group.

Everything else — cold chain, documentation depth, lead time and price per gram — follows from which of those three facts applies.